Welcome to Vesalius Biocapital with Stéphane Verdood, Managing Director !

Let's learn more about ...

VESALIUS BIOCAPITAL

Vesalius Biocapital is a European venture capital firm based in Luxembourg specializing in life sciences, with a focus on therapeutics, medical devices, diagnostics, and digital health. Since its inception in 2007, the firm has raised multiple funds to support innovative healthcare companies across Europe.

Investment Strategy

The firm recently launched its fourth fund, Vesalius Biocapital IV, securing over € 110 million in its first closing, with a target of € 150 million. This fund aims to support 10–12 companies, with investments ranging from € 10–15 million per deal, and reserves 50–70 % for follow-on investments. 

Fund III (Vesalius Biocapital III)

Launched in 2017 and closed in 2019 with € 120 million in commitments, Fund III targets later-stage European life science companies. The fund focuses on drug development, medtech, diagnostics, and digital health sectors. 

Notable Portfolio Companies

• Sword Health: A digital health company offering AI-powered physical therapy solutions for musculoskeletal disorders. 
• Forendo pharma: Develops tissue-specific hormone therapies, including treatments for endometriosis. 
• Mecuris: Provides a digital platform for designing and 3D-printing customized orthotics and prosthetics. 
• Dearhealth: Offers AI-powered care pathways to improve chronic disease management.
• OncoDNA: Specializes in precision medicine through comprehensive genomic profiling for cancer treatment. 
• Topas Therapeutics: Develops nanoparticle-based therapies to induce immune tolerance for autoimmune diseases. 
• CatalYm: Focuses on cancer immunotherapies targeting the GDF-15 protein to enhance anti-tumor immune responses. 
• Memo Therapeutics: Engages in antibody discovery and development for infectious diseases and immuno-oncology. 
• Rejuvenate Biomed: Develops drugs aimed at delaying age-related functional decline by restoring cellular resilience. 
• Caresyntax: Provides a digital surgery platform that uses AI to improve surgical outcomes and operational efficiency. 

Previous Funds and Exits

Vesalius Biocapital's earlier funds, I and II, raised over € 150 million and contributed to the development of more than 20 companies. Notable exits include:

• Ogeda: Acquired by Astellas for € 800 million. 
• Activaero: Sold to Vectura for € 130 million. Fovea Pharmaceuticals: Acquired by Sanofi for € 370 million. 
• GenKyoTex: technology acquired by Callidatas. 

The firm continues to support innovative life science companies, leveraging its experienced team to drive growth and value creation in the healthcare sector.

Based in Contern, Luxembourg, Vesalius Biocapital IV Partners SàRL is led by a team of seasoned professionals with expertise in healthcare, corporate finance, and strategy development.